Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
4/23/26 Novo Nordisk (NVO) Rybelsus for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
4/23/26 AbbVie (ABBV) Trenibote for Wrinkles Subscribers Only Subscribers Only Subscribers Only
4/22/26 Anthos Therapeutics abelacimab for Venous Thromboembolism (VTE) Subscribers Only Subscribers Only Subscribers Only
4/21/26 CytoDyn (CYDY) Vyrologix for Colorectal Cancer (CRC) Subscribers Only Subscribers Only Subscribers Only
4/21/26 Praxis (PRAX) PRAX-944 for Essential Tremor Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results